Latest Conference Articles

Detection of positive circulating tumor cells in the blood 5 years after a breast cancer diagnosis was associated with an increased risk for late recurrence in women with HR–positive, HER2-negative breast cancer

Treatment with the combination of pembrolizumab (Keytruda) and eribulin (Halaven) demonstrated a 26.4% objective response rate for patients with metastatic triple-negative breast cancer.

Harold Burstein, MD, PhD, medical oncologist, Dana-Farber Cancer Institute discusses some key findings from the follow-up data from the SOFT trial.

Losing even some extra weight significantly reduces the risk of breast cancer for postmenopausal women, expert says.

Neoadjuvant treatment with abemaciclib (Verzenio) plus anastrozole induced complete cell cycle arrest as measured by Ki67 for 67.8% of patients with HR-positive/HER2-negative early-stage breast cancer.

Older women with HR–positive breast cancer treated with a CDK4/6 inhibitor may derive a progression-free survival benefit similar to that seen in their younger counterparts

The PARP inhibitor talazoparib reduced the risk of disease progression or death by 46% versus chemotherapy in patients with BRCA-positive advanced breast cancer.

Dawn Hershman, MD, MS, professor of Medicine and Epidemiology, Columbia University Medical Center, discusses the use of acupuncture to treat joint pain caused by aromatase inhibitors in patients with breast cancer.

Substituting nab-paclitaxel (Abraxane) for solvent-based paclitaxel as neoadjuvant chemotherapy improved disease-free survival in patients with high-risk early breast cancer.

Susan Domchek, MD, director of the Basser Center for BRCA at Penn Medicine, discusses some questions that remain after the recent phase II MEDIOLA trial.

Halle Moore, MD, medical oncologist, the Cleveland Clinic, discusses the use of GnRH agonists to preserve ovarian function and fertility in women with breast cancer.

Treatment with nab-paclitaxel showed promising improvements in overall survival and progression-free survival compared with standard paclitaxel for patients with metastatic triple-negative breast cancer.

Key opinion leaders share their insight on the pivotal and highly anticipated abstracts across hematologic malignancies, including lymphoma, leukemia, and multiple myeloma, ahead of 2017 ASH Annual Meeting and exactly how these findings could be implemented in and affect clinical practice.

Investigators with the Austria Breast and Colorectal Cancer Study Group announced today that years can safely be shaved off anastrozole (Arimidex) treatment without affecting disease-free survival postmenopausal HR-positive breast cancer.

A mix of traditional and customized acupuncture techniques proved effective in reducing pain and stiffness associated with aromatase inhibitor (AI) therapy in women with early-stage breast cancer.

The phase III SOLD trial failed to demonstrate that DFS with 9 weeks of adjuvant trastuzumab was noninferior to the standard 12 months when the 2 regimens were combined with chemotherapy in women with early stage HER2-positive breast cancer.

Results from a meta-analysis of data collected from 837 premenopausal women undergoing chemotherapy for early-stage breast cancer suggest that gonadotropin-releasing hormone analog may preserve fertility and have a protective ovarian function.

Charles Coombes, MD, professor of medical oncology, Imperial College London, discusses surprising results from a recent study examining celecoxib’s impact on breast cancer progression and relapse.

Mothaffar F. Rimawi, MD, associate professor and director of clinical research at the Lester and Sue Smith Breast Center at Baylor College of Medicine, discusses the clinical need for immunotherapy regimens for patients with HER2-positive breast cancer.

Newly released results from the MONALEESA-7 trial showed that adding ribociclib to standard endocrine therapy with temporary ovarian suppression significantly improved progression-free survival as a first-line treatment for pre- and perimenopausal women with advanced HR-positive/HER2-negative breast cancer.

Julie R. Nangia, MD, assistant professor of medicine, Baylor College of Medicine, discusses some logistical factors that oncologists and health care providers should know regarding implementing a scalp cooling system.

The combination of pembrolizumab and trastuzumab reached an objective response rate of 15.2% in patients with trastuzumab-resistant, PD-L1–positive, HER2-positive breast cancer.

Shortening the intervals between chemotherapy cycles or administering the drugs sequentially reduced early-stage breast cancer recurrence and mortality compared with standard dosing techniques.

Treatment with sacituzumab govitecan elicited an objective response rate of 34% in patients with heavily pretreated metastatic triple-negative breast cancer.

A trial to determine the value of trastuzumab plus standard adjuvant chemotherapy in patients with low levels of HER2 protein has shown no significant efficacy, confounding investigators who launched the trial based on opposing results from 2 earlier studies.

Treatment with neoadjuvant chemotherapy prior to radical cystectomy significantly improved overall survival compared with cystectomy alone for patients with the basal subtype of muscle-invasive bladder cancer.

In a study of neoadjuvant sonidegib in men with high-risk localized prostate cancer undergoing prostatectomy, hedgehog pathway activity was detectable at baseline.

Prostate cancer has recently been recognized as a genomically heterogeneous disease with subtypes similar to breast or ovarian cancers.

Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses neoadjuvant immunotherapy trials in renal cell carcinoma (RCC).

Andrea B. Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses managing toxicities with checkpoint inhibitors in bladder cancer.